Pipeline of
Novel Targets

At HotSpot, we are advancing a pipeline of therapeutic candidates for the treatment of cancer and autoimmune diseases where there remains a significant unmet need. Our Smart Allostery™ platform has allowed us to deliver differentiated small molecule allosteric inhibitors that address key challenges for targets with deep genetic and/or biologic validation.

Program Lead Candidate
Indication
Discovery
IND-enabling
Ph 1
Ph 2
Ph 3
Product rights
Oncology
Oncology
Program Lead Candidate
CBL-B HST-1011
Indication
Solid tumors
Stage
Phase 1
Logo HotSpot Therapeutics

CBL-B

Casitas B-lineage Lymphoma-B, or CBL-B, is an E3 ubiquitin protein ligase critically involved in immune cell response. CBL-B is a master regulator of effector cell (T cell and natural killer cell) immunity, and its elimination or inactivation removes its endogenous negative regulatory functions to substantially enhance anti-tumor immunity. Robust preclinical data demonstrate a central role of CBL-B inhibition to immune cell activation and immune-mediated tumor growth inhibition in vivo, supporting the therapeutic potential of this mechanism.

Our lead development candidate, HST-1011, has the potential to be a first-in-class selective, orally bioavailable, small molecule targeting CBL-B for the treatment of patients with solid tumors. HST-1011 was designed to have picomolar binding affinity, low nanomolar potency, slow rate of dissociation from the target to enable potency and sustained pharmacology, and greater selectivity for CBL-B relative to C-CBL, another E3 ligase originating from the same protein superfamily. The planned Phase 1 evaluation of HST-1011 will focus on patients who are relapsed or refractory to anti-PD(L)1-based therapies as an opportunity to demonstrate both the biological effects of CBL-B inhibition in humans and to support the opportunity to address significant clinical need.

Oncology
Program Lead Candidate
MALT1 HST-1021
Indication
Precision Oncology
Stage
IND-enabling
Logo HotSpot Therapeutics

MALT1

MALT1 is a component of the CARD11-BCL10-MALT1 (CBM) protein complex, which serves as a key regulator of NFkB signaling in cells, including B and T cells. MALT1 is implicated in a range of hematological malignancies, including Non-Hodgkin’s lymphoma, as well as other lymphomas and selected solid tumors. Leveraging our proprietary Smart AllosteryTM platform, HotSpot has developed first-in-class small molecules designed to selectively inhibit the scaffolding function of MALT1, a dominant driver of the NFkB pathway. HotSpot’s scaffolding inhibitor has a differentiated preclinical profile, including the potential for an improved efficacy and safety profile versus traditional MALT1 inhibitors that target protease function.

Inflammation
Inflammation
Program
IRF5
Indication
SLE,
 Sjögren’s,RA, 
SSc, myositis
Stage
Discovery
logo abbvie

IRF5

Interferon regulatory factor 5, or IRF5, is a transcription factor involved in a diverse range of biological activities in which it functions as a master regulator of innate immunity. Genome-wide association studies have established compelling evidence as to the involvement of IRF5 in multiple inflammatory and immune system disorders, including SLE, making it a development target of significant interest. Historical efforts to modulate IRF5 using traditional small molecule approaches have been unsuccessful because IRF5 lacks a traditional active site. Leveraging our proprietary Smart Allostery™ platform, we believe we have discovered the first and only small molecule IRF5 inhibitors that bind to a previously unknown allosteric pocket on the protein that is critical for its endogenous regulation.

In collaboration with AbbVie, we are developing our IRF5 inhibitor program for the treatment of multiple autoimmune diseases including SLE, Sjögren’s, RA, SSc and myositis.

Inflammation
Program
Undisclosed
Indication
Serious Autoimmune Disorders
Stage
Discovery
Logo HotSpot Therapeutics

Serious Autoimmune Disorders

Our undisclosed immunology program is designed to inhibit a genetically validated target with strong disease associations for a range of serious autoimmune diseases. At HotSpot, we are leveraging our Smart Allostery™ platform to develop differentiated inhibitors for this target.

Focus on Patients
and Value Creation

Our pipeline is further enabled by biomarker-driven, patient-targeted approaches in oncology and autoimmune diseases. To support these efforts, in 2021, we entered into a collaboration with Caris Life Sciences.

We believe Caris’ comprehensive suite of tissue and liquid profiling, real-world data, and broader capabilities will enable robust interrogation of large datasets, yielding data-informed insights to inform and speed clinical development and deliver new treatment options to patients.

Presentations

November 9, 2024

Peripheral Blood and Tumor Gene Expression as Biomarkers and Potential Predictors of Clinical Outcome with HST-1011, an Oral CBL-B Inhibitor

Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting
October 23, 2024

Targeting the CBM Signalosome with a MALT1 Signalosome Glue for Treatment of NFκB Driven Solid Tumors

36th EORTC-NCI-AACR Symposium
September 13, 2024

First-in-Human (FIH) Phase 1 Data of HST-1011, an Oral CBL-B Inhibitor, in Patients with Advanced Solid Tumors

European Society for Medical Oncology Congress 2024
June 20, 2024

Targeting the CBM Signalosome with a MALT1 Scaffolding Inhibitor for Treatment of Non-Hodgkin Lymphomas

American Association for Cancer Research Annual Meeting 2024
December 9, 2023

Discovery of the First MALT1 Allosteric Scaffolding Inhibitor

2023 American Society of Hematology Annual Meeting
November 3, 2023

Exploring Proximal Biomarkers of CBL-B Inhibition in Human Peripheral Blood Mononuclear Cells

Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting
April 19, 2023

Inhibition of the E3 Ligase CBL-B Enhances the Effector Function and Proliferation of Natural Killer (NK) Cells

American Association for Cancer Research Annual Meeting 2023
April 18, 2023

Phase 1/2 Study of HST-1011, an Oral CBL-B Inhibitor, Alone and in Combination with Anti-PD-1 in Patients with Advanced Solid Tumors

American Association for Cancer Research Annual Meeting 2023
November 11, 2022

CBL-B Inhibition Showed Differentiated Effects in a Mixed Lymphocyte Reaction Versus Other Immuno-oncology Targeted Approaches

Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting
November 11, 2022

An Allosteric, Orally Administered CBL-B Inhibitor Remodels the Tumor Microenvironment and Enhances Immune-mediated Tumor Growth Inhibition

Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting
April 10, 2022

A Novel Allosteric CBL-B Inhibitor with Differentiated Immune Enhancing Activity in Preclinical Models

American Association for Cancer Research Annual Meeting 2022
November 10, 2021

Identification of A Novel Allosteric Oral CBL-B Inhibitor that Augmented T Cell Response and Enhanced NK Cell Killing in vitro and in vivo

Society for Immunotherapy of Cancer (SITC) 2021 Annual Meeting

Our Team

HotSpot Therapeutics is led by a team of seasoned drug hunters with substantial industry and R&D expertise.

Our Team